MITD1

Across TCGA pan-cancer cohorts, MITD1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MITD1 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MITD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MITD1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and GBM are the cancer types where MITD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.744	0.357	.013	13	view →
LSCC	DFS	Tertile	All	0.926	0.388	.016	3	view →
GBM	OS	Median	All	0.633	0.303	.012	3	view →
CCRCC	DFS	Median	II,III,IV	0.787	0.502	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MITD1–LUAD (DFS)

Open the LUAD breakdown →